Damian Smedley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Damian Smedley has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Colin Cooper
3 shared publications- Janet Shipley
The Institute of Cancer Research, London, UK
3 shared publications Deon Venter
Department of Pathology, Peter MacCallum Cancer Institute , East Melbourne, Victoria, Australia
2 shared publicationsGino Somers
Department of Pathology, Peter MacCallum Cancer Institute , East Melbourne, Victoria, Australia
2 shared publications- Rifat Hamoudi
Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates
2 shared publications Chung Wo Chow
Department of Anatomical Pathology, Royal Children's Hospital, Parkville, Victoria, Australia
1 shared publication
Latest Publications
- Open Access
- 1 April 1998
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 7 (4) , 637-642
The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP
A recently described atypical myeloproliferative disorder is invariably associated with reciprocal translocations involving 8p11–12. The most common rearrangement is a t(8;13)(p11;q11–12). Here we determine that this translocation results in the fusion of the fibroblast growth factor receptor 1 gene (FGFR1), a member of the receptor tyrosine kinase family at 8p11, to a novel gene at 13q11–12 designated RAMP. The predicted RAMP protein exhibits strong homology to the product of a recently cloned candidate gene for X-linked mental retardation, DXS6673E. We also provide the first report of a novel, putative metal-binding motif, present as five tandem repeats in both RAMP and DXS6673E. RT-PCR detected only one of the two possible fusion transcripts, encoding a product in which the N-terminal 641 amino acids of RAMP become joined to the tyrosine kinase domain of FGFR1. Receptor tyrosine kinases are not commonly involved in the formation of tumour-specific fusion proteins. However, the previous reports of involvement of receptor tyrosine kinases in fusion proteins in non-Hodgkin's lymphoma, chronic myelomonocytic leukaemia and papillary thyroid carcinoma described similar rearrangements. By analogy with these, we propose that the RAMP-FGFR1 fusion product will contribute to progression of this myeloproliferative disorder by constitutive activation of tyrosine kinase function.
- 1 April 1998
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 7 (4) , 637-642
Open AccessThe t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP
A recently described atypical myeloproliferative disorder is invariably associated with reciprocal translocations involving 8p11–12. The most common rearrangement is a t(8;13)(p11;q11–12). Here we determine that this translocation results in the fusion of the fibroblast growth factor receptor 1 gene (FGFR1), a member of the receptor tyrosine kinase family at 8p11, to a novel gene at 13q11–12 designated RAMP. The predicted RAMP protein exhibits strong homology to the product of a recently cloned candidate gene for X-linked mental retardation, DXS6673E. We also provide the first report of a novel, putative metal-binding motif, present as five tandem repeats in both RAMP and DXS6673E. RT-PCR detected only one of the two possible fusion transcripts, encoding a product in which the N-terminal 641 amino acids of RAMP become joined to the tyrosine kinase domain of FGFR1. Receptor tyrosine kinases are not commonly involved in the formation of tumour-specific fusion proteins. However, the previous reports of involvement of receptor tyrosine kinases in fusion proteins in non-Hodgkin's lymphoma, chronic myelomonocytic leukaemia and papillary thyroid carcinoma described similar rearrangements. By analogy with these, we propose that the RAMP-FGFR1 fusion product will contribute to progression of this myeloproliferative disorder by constitutive activation of tyrosine kinase function.
- 1 January 1998
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 21 (1) , 70-73
Characterization of a t(8;13)(p11;q11‐12) in an atypical myeloproliferative disorder
- 1 January 1998
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 21 (1) , 70-73
Characterization of a t(8;13)(p11;q11‐12) in an atypical myeloproliferative disorder